LIN28B-dependent fetal B- and NK-lymphopoiesis - the NORMAL state the leukaemia requirement is parasitic on, and the reason the therapeutic window is narrow by construction
also called fetal B-lymphopoiesis · LIN28B-dependent fetal lymphoid output · the normal arm of Ling 2026
Before birth, blood stem cells need LIN28B in order to keep multiplying, stay stem-like, and make B cells and NK cells at all. That is normal biology, not cancer biology - which is why removing LIN28B stops infant leukaemia starting and also stops the baby's own immune system being built.
The same thing, for a scientist
Ling et al. report that in human fetal liver CD34+ cells, **LIN28B is essential to maintain proliferation and stem-like properties and to support B- and NK-lymphopoiesis** [E1]. This is the normal-development arm of the same paper that shows the KMT2A::AFF1 transformation requirement, and it is a distinct object from that requirement: it describes a **state of a normal cell**, not a property of a leukaemia. The graph holds it separately for two reasons. **First, it is the control the transformation result needs.** If a LIN28B-null fetal CD34+ cell is no longer a proliferating, stem-like, lymphoid-competent progenitor, then 'fails to transform on KMT2A::AFF1 induction' may be a statement about the competence of the target cell rather than a statement about the fusion. Nothing readable from the abstract separates the two. **Second, it is the entire bite-back.** Every LIN28B-directed intervention in an infant is aimed at a gene the infant's own lymphopoiesis is using. The mouse literature supports the normal-state claim independently, and in a different lineage: the Lin28b-let-7-Hmga2 axis is a bidirectional developmental clock for myeloerythroid output [E2], and enforced Lin28b reprograms adult haematopoiesis toward fetal-type lymphoid output in published work that this beat did not independently verify (see caveats).
What the state consists of, and what is asserted versus assumed
| feature | source | strength |
|---|---|---|
| proliferation maintained by LIN28B in human FL CD34+ | Ling 2026, abstract 1 | asserted by the authors, abstract-only here |
| stem-like properties maintained by LIN28B | Ling 2026, abstract 1 | asserted, abstract-only; 'stem-like' is undefined in the abstract |
| B-lymphopoiesis supported by LIN28B | Ling 2026, abstract 1 | asserted, abstract-only |
| NK-lymphopoiesis supported by LIN28B | Ling 2026, abstract 1 | asserted, abstract-only; the NK arm is the least expected part and the one with least corroboration |
| LIN28B expression is fetal-restricted and falls postnatally | Rowe 2016 (mouse CMP) 2; Li 2024 (mouse, adult progenitors and MLL::ENL AML do not express Lin28b transcript) 3 | strong, but mouse and myeloid |
| a fetal-specific signature derived from human fetal vs adult HSPC has LIN28B among top hits, and those genes are expressed in infant ALL | Ling 2026, abstract 1 | asserted, abstract-only |
The NK arm deserves a flag of its own. B- and NK-lymphopoiesis both descend from lymphoid progenitors, so a shared requirement is plausible, but this graph holds no other evidence for a LIN28B-NK link and the entry should not be read as establishing one. If it is real, it widens the toxicity concern - NK cells are the arm of immunity a leukaemic infant can least afford to lose, and are also the effector cells of several immunotherapies used in this disease.
The control this state implies, which is the most important experiment named anywhere in this beat
The transformation result and the normal-biology result are the same perturbation read two ways:
LIN28B knockout in human FL CD34+
|-- normal arm: proliferation down, stem-like properties down, B/NK output down
|-- leukaemia arm: KMT2A::AFF1 induction produces no transformation
Those two arms are not independent. A cell that has stopped proliferating and lost stem-like properties is a poor substrate for any oncogene. To claim a specific requirement for KMT2A::AFF1 transformation, one needs a second oncogene run in the same LIN28B-null cells - ideally one whose transformation is known not to depend on the fetal state.
Whether Ling et al. did this cannot be determined: the paper is paywalled and absent from PMC and Europe PMC (verified 2026-09-23). It is entirely possible they did and the abstract simply has no room. The honest position for this graph is that the specificity control is unread, not absent, and the experiment is written down as exp-lin28b-null-fetal-progenitor-second-oncogene-specificity-control so that a reader with access can either discharge it or run it.
Where this sits relative to the fetal entries already here
cell-type-fetal-liver-hscis the cell - the compartment and its markers, and the case that it is the cell of origin.cell-state-fetal-program-retentionis the leukaemia's state - infant blasts keeping the fetal signature that childhood KMT2A::AFF1 blasts do not.- This entry is the normal cell's state - what a healthy fetal progenitor is doing with LIN28B before any fusion exists.
The three are easy to merge and should not be. The retention entry's claim is that the leukaemia keeps a fetal setting; this entry's claim is that the setting itself is a LIN28B-dependent functional programme in normal development. The first is a description of blasts; the second is a requirement in healthy tissue, and it is the one with the toxicity consequence.
| state definition | The functional programme of a normal human fetal liver CD34+ haematopoietic stem/progenitor cell in which LIN28B is required to maintain proliferation and stem-like properties and to support B- and NK-lymphoid output. It is a state of healthy tissue, not of leukaemia. |
|---|---|
| ontology | no Cell Ontology term applies - this is a functional state of cells already typed as CL fetal liver HSPC; see cell-type-fetal-liver-hsc for the cell's own ontology id |
| location | human fetal liver (first/second trimester definitive haematopoiesis), before the transition to fetal bone marrow |
| requires | LIN28B |
| species | human (the primary claim); mouse corroborates the developmental timing in a different lineage |
| relationship to transformation | The SAME perturbation that abolishes this normal state abolishes KMT2A::AFF1 transformation in the same cells. Whether the transformation block is specific to the fusion or secondary to loss of progenitor competence is UNRESOLVED from the abstract and is the key missing control. |
| therapeutic consequence | A LIN28B-directed agent in an infant targets a gene the infant's own B- and NK-lymphopoiesis requires. The window is narrow by construction, not by accident. |
| read depth | primary claim ABSTRACT-ONLY and paywalled; corroborating mouse work abstract-only; Li 2024 full text read |
| shown for fusion | N/A - this is normal biology. The adjacent transformation claim is shown for KMT2A::AFF1 in human fetal cells. |
markers
[ "LIN28B expression (fetal-restricted; falls postnatally)", "low mature let-7 (inferred from the axis, NOT measured in human fetal B progenitors)", "the fetal-specific HSPC signature of Ling et al., derived from human fetal vs adult HSPC transcriptomes" ]
outputs affected
[ "proliferation", "stem-like properties (undefined in the source abstract)", "B-lymphopoiesis", "NK-lymphopoiesis" ]
atlas refs
[ "the fetal-specific HSPC signature of Ling et al. 2026 (not deposited/accessible to this beat)" ]
- This is the toxicity entry for the whole beat: the target gene is required for normal human fetal B- and NK-lymphopoiesis, in the same experiment that makes it interesting.
- If LIN28B is needed for progenitor proliferation generally, a LIN28B inhibitor would be myelosuppressive on top of chemotherapy in patients who are already cytopenic.
- Infants with KMT2A::AFF1 ALL are treated with blinatumomab and CAR-T approaches whose efficacy depends on lymphoid and NK compartments. Suppressing lymphoid output to block a fetal programme could directly antagonise the immunotherapy backbone.
- The state is defined by a fetal restriction, which means it is also self-limiting: it disappears with age. A therapy aimed at it has a shrinking target in a growing patient, and a relapse after the programme has lapsed would be untouched by it.
- Is the KMT2A::AFF1 transformation block specific to the fusion, or is it downstream of losing a competent proliferating progenitor? A second oncogene in the same LIN28B-null cells is the control, and it is unread rather than known-absent.
- How severe is the normal phenotype - a shift in lineage output, as in mouse, or a loss of progenitor function? The two imply very different toxicity ceilings for a LIN28B-directed agent.
- Is the NK requirement real and does it persist? NK cells matter both for infant immunity and as effectors of immunotherapies used in KMT2A-rearranged ALL, so a LIN28B agent that suppresses NK output could antagonise the rest of the regimen.
- When exactly does LIN28B fall in HUMAN haematopoiesis, and does the fall coincide with the postnatal window in which KMT2A::AFF1 infants actually present? The mouse timing is documented; the human timing is what an epidemiological argument would need.
- E1strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Functional assays revealed that LIN28B was essential in human fetal liver CD34+ cells to maintain proliferation and stem-like properties, and to support B- and NK-lymphopoiesis; a fetal-specific gene signature derived by comparing human fetal and adult HSPC transcriptomes had LIN28B and its downstream effectors among the top hits, and those genes were also expressed in infant ALL.
The fetal specific gene LIN28B is essential for human fetal B-lymphopoiesis and initiation of KMT2A::AFF1 infant leukemia. · Ling RE, Welsh AM, Hamer L, Jackson T, Neil E, Elliott N, Cross JW, Wuppalapati AS, Smith AL, Chahrour C, Sevim O, Palmer DA, Bozhilov Y, Brown EJ, Olender L, Iskander D, Wang G, Rice S, O'Byrne S, Harman J, Ancliff P, Psaila B, Wilkinson AC, Morgan RG, Roberts IA, Milne TA, Roy A · Blood 2026What this evidence cannot show
ABSTRACT ONLY AND PAYWALLED - Europe PMC returns isOpenAccess N, inEPMC N, inPMC N for this DOI, verified live 2026-09-23. Consequences: 'stem-like properties' is not operationally defined here; the assays behind 'B- and NK-lymphopoiesis' are unknown (in vitro differentiation? xenograft?); donor number, gestational ages and effect sizes are unknown; and the knockout method and its efficiency are unknown. The NK claim in particular has no corroboration anywhere else in this graph. Identifiers were fetched live from PubMed on 2026-09-23 and the PMID resolves to this exact title and author list.
Evidence that argues against this (1)
- In mouse, deleting Lin28b in fetal progenitors shifts haematopoietic output toward adult-like myeloid dominance rather than abolishing progenitor function, and conditional Lin28b deletion in fetal progenitors was compatible with normal survival in a leukaemia model - so a complete loss of proliferative and stem-like capacity is not the mouse phenotype, and the human severity claim rests on this one paper. J Exp Med 2016
- E2strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Lin28b expression decreases in mouse common myeloid progenitors as haematopoiesis matures, with mature let-7 accumulating in step; inhibiting let-7 in adults recapitulates fetal erythroid-dominant haematopoiesis, and deleting Lin28b or activating let-7 in the fetal state shifts output toward adult-like myeloid dominance, with Hmga2 as an effector.
Developmental regulation of myeloerythroid progenitor function by the Lin28b-let-7-Hmga2 axis. · Rowe RG, Wang LD, Coma S, Han A, Mathieu R, Pearson DS, Ross S, Sousa P, Nguyen PT, Rodriguez A, Wagers AJ, Daley GQ · J Exp Med 2016What this evidence cannot show
Abstract read; full text not opened. MOUSE, MYELOERYTHROID output, normal haematopoiesis. It establishes Lin28b as a causal developmental-timing factor, which corroborates the general shape of the human claim, but it measures a different lineage from the B/NK one and reports a SHIFT in output rather than a loss of progenitor function.
Evidence that argues against this (1)
- This is a MYELOERYTHROID result used to corroborate a B- and NK-lymphoid claim. The Lin28b-let-7-Hmga2 axis setting developmental timing in common myeloid progenitors does not establish that LIN28B is required for B- or NK-lymphopoiesis, and the one paper that claims the lymphoid requirement is abstract-only here. Corroboration across lineages is weaker than it looks. Blood 2026
- E3strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Adult mouse haematopoietic progenitors and MLL::ENL-driven AML cells do not express Lin28b transcript, and most human paediatric AML including MLL-rearranged AML do not express LIN28B while expressing several let-7 family microRNAs at high levels.
LIN28B promotes differentiation of fully transformed AML cells but is dispensable for fetal leukemia suppression. · Li Y, Mendoza-Castrejon J, Patel RM, Casey EB, Denby E, Bryder D, Magee JA · Leukemia 2024What this evidence cannot show
FULL TEXT READ from PMC10912017. Both statements are supported in the paper by supplementary figures that were not themselves inspected here (the full text refers to 'Supplementary Fig.' without the figure being reproduced in the text stream retrieved). The human paediatric AML expression claim is a re-analysis of external data, not a primary measurement in this paper. Note the scope: it is about AML, not about infant B-ALL, and it is the postnatal/adult side of the axis - it corroborates that LIN28B is fetal-restricted, not that it is required in fetal cells.
Evidence that argues against this (1)
- This is the postnatal/adult side of the axis and it corroborates only that LIN28B is fetal-restricted. It says nothing about whether LIN28B is REQUIRED in fetal cells, which is this entry's actual claim, and the expression statements rest on supplementary figures and on re-analysis of external data rather than on primary measurement. Leukemia 2024
LIN28B is essential to maintain proliferation, stem-like properties and B/NK output in human FL CD34+
- expressed in →Fetal liver haematopoietic stem and progenitor cell — the leading candidate cell of origin for t(4;11) infant ALL
the state of this cell before any fusion exists
B-lymphoid output of the LIN28B-dependent fetal progenitor
the same perturbation abolishes normal progenitor competence, so the transformation block may not be fusion-specific
the axis that ends this state as development proceeds (mouse, myeloerythroid)
the normal state whose retention in blasts the other entry describes
the normal-biology arm is what makes the control necessary
liability 1 - the normal state that shares the target
the fetal-restriction pattern: LIN28B on the lymphoid side, CSF1R on the myeloid side of the same ontogeny argument